Projects funded by the NCN

Study of casein kinase CK2 inhibition mechanisms

Call: OPUS 1 , Panel: ST5

Principal investigator: prof. Maria Wanda Bretner

Politechnika Warszawska, Wydział Chemiczny

The study of synergistic inhibition of tumor cell proliferation by CK2 casein kinase inhibitors and inhibitors of thymid...

Call: OPUS 7 , Panel: NZ7

Principal investigator: prof. Maria Wanda Bretner

Politechnika Warszawska, Wydział Chemiczny

Understanding the mechanism of action for small molecule kinase inhibitors in alleviating myotonic dystrophy type 1 (DM1...

Call: OPUS 7 , Panel: NZ5

Principal investigator: dr hab. Marzena Wojciechowska

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

Studies on the influence of selected inhibitors of kinases involved in signaling pathways in tumor cells on NK cell cyto...

Call: PRELUDIUM 7 , Panel: NZ6

Principal investigator: Marta Siernicka

Warszawski Uniwersytet Medyczny, I Wydział Lekarski

Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

Call: OPUS 6 , Panel: NZ7

Principal investigator: dr hab. Sylwia Flis

Narodowy Instytut Leków

Inhibitors of ER stress dependant PERK kinase as a novel approach for Alzheimer's therapy

Call: HARMONIA 5 , Panel: NZ1

Principal investigator: prof. Ireneusz Jacek Majsterek

Uniwersytet Medyczny w Łodzi, Wydział Wojskowo-Lekarski

Mechanism regulating vitamin D analog cooperation with cytostatics and tyrosine kinase inhibitors in non-small cell lung...

Call: PRELUDIUM 5 , Panel: NZ4

Principal investigator: dr Ewa Agnieszka Maj

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Kinases of emerging relevance in cancer - structural characterization.

Call: SONATA BIS 2 , Panel: NZ1

Principal investigator: dr Grzegorz Dubin

Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

Analysis of pharmacokinetic, pharmacodynamic and molecular determinants of intolerance and resistance to the Janus kinas...

Call: OPUS 27 , Panel: NZ7

Principal investigator: dr hab. Marta Katarzyna Karaźniewicz-Łada

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Selective inhibition of Janus kinases for the treatment of autoimmune hepatitis: Translational PK/PD modelling from mole...

Call: SONATA 19 , Panel: NZ7

Principal investigator: dr Artur Świerczek

Uniwersytet Jagielloński, Collegium Medicum

Targeting adenylate kinase 4 (AK4) as a new paradigm in the treatment of non-small cell lung cancer: discovery and evalu...

Call: OPUS 26 , Panel: NZ7

Principal investigator: dr Magdalena Wujak

Uniwersytet Mikołaja Kopernika w Toruniu, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy

Novel aspects of the mechanisms of vascular toxicity of tyrosine kinase inhibitors: studies on their proinflammatory act...

Call: OPUS 26 , Panel: NZ5

Principal investigator: dr Tomasz Krzysztof Prajsnar

Uniwersytet Jagielloński, Wydział Biologii

Investigating the mechanisms of CD20 downregulation triggered by tyrosine kinase inhibitors in Philadelphia chromosome-p...

Call: PRELUDIUM 22 , Panel: NZ5

Principal investigator: Krzysztof Domka

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

Search for novel IKK-β inhibitors in the context of diseases with neuroinflammatory origin – structure-based drug design...

Call: PRELUDIUM 22 , Panel: NZ7

Principal investigator: Emilia Aleksandra Sługocka

Uniwersytet Jagielloński, Collegium Medicum

Targeting Energy Metabolism for Precision Cancer Therapy: Novel Inhibitors of LDH-A and PDK1 as Potential Strategies to ...

Call: PRELUDIUM 22 , Panel: NZ7

Principal investigator: Marika Anna Frańczak

Gdański Uniwersytet Medyczny, Wydział Lekarski

Effects of tyrosine kinase inhibitors on Syk pathway in eNOS-based platelet subpopulations and on endothelial barrier in...

Call: POLONEZ BIS 3 , Panel: NZ7

Principal investigator: dr hab. Aneta Iwona Radziwon-Balicka

Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

Small-molecule inhibitors of protein aggregation and ER stress as a novel strategy against neurodegeneration in the cour...

Call: PRELUDIUM BIS 3 , Panel: NZ5

Principal investigator: prof. Ireneusz Jacek Majsterek

Uniwersytet Medyczny w Łodzi

New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

Call: SONATA 17 , Panel: NZ7

Principal investigator: dr Anna Katarzyna Florczak-Substyk

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized...

Call: PRELUDIUM 20 , Panel: NZ7

Principal investigator: Mikołaj Czajkowski

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Iron chelators as tyrosine kinase inhibitors - a new strategy for the treatment of glioblastoma multiforme

Call: PRELUDIUM BIS 2 , Panel: NZ5

Principal investigator: dr hab. Anna Dominika Mrozek-Wilczkiewicz

Uniwersytet Śląski w Katowicach, Wydział Nauk Ścisłych i Technicznych

Cell-based high-throughput screening for small-molecule compounds diminishing molecular markers of pathogenesis in myoto...

Call: OPUS 20 , Panel: NZ3

Principal investigator: dr hab. Marzena Wojciechowska

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

A novel approach based on the optimized multidrug combination for glioblastoma treatment.

Call: SONATA 16 , Panel: NZ7

Principal investigator: prof. Małgorzata Kucińska

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Molecular mechanisms of interplay between RORγ/RORγT receptors and cyclin-dependent kinase inhibitor (AT7519). Analysis ...

Call: PRELUDIUM 18 , Panel: NZ7

Principal investigator: Kaja Urszula Karaś

Instytut Biologii Medycznej Polskiej Akademii Nauk

Restoration of beta-cell function via inhibition of diabetic kinome.

Call: SONATA BIS 9 , Panel: NZ1

Principal investigator: dr Anna Czarna

Uniwersytet Jagielloński

The use of olaparib and ATR / CHK1 kinase inhibitors as a targeted anti-cancer therapy based on synthetic lethality

Call: SONATA BIS 9 , Panel: NZ7

Principal investigator: dr hab. Aneta Katarzyna Rogalska

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Multitarget approach to break the vicious circle of tau pathology and neuroinflammation in Alzheimer's disease: developm...

Call: SONATA BIS 9 , Panel: NZ7

Principal investigator: dr hab. Anna Karolina Więckowska

Uniwersytet Jagielloński, Collegium Medicum

Comparative evaluation of effects of tyrosine kinase inhibitors (TKIs) on endothelial function in vivo in mice

Call: PRELUDIUM 17 , Panel: NZ5

Principal investigator: Brygida Elżbieta Marczyk

Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

The significance of cancer specific PFK-II (PFKFB3 and PFKFB4) isoenzymes inhibition in overcoming resistance to BRAF in...

Call: PRELUDIUM 16 , Panel: NZ5

Principal investigator: Sonia Elżbieta Trojan

Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum

Deciphering molecular mechanism of CDK8 kinase inhibitors action in acute myeloid leukemia

Call: SONATA BIS 8 , Panel: NZ2

Principal investigator: dr hab. Michał Marek Mikula

Narodowy lnstytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy lnstytut Badawczy

Design of new small molecular regulators (inhibitors, activators) of the catalytic activity of adenylate kinases. Molecu...

Call: OPUS 13 , Panel: ST4

Principal investigator: dr Anna Kozakiewicz-Piekarz

Uniwersytet Mikołaja Kopernika w Toruniu, Wydział Chemii

Insights into biological activity and mechanism of action of novel styrylquinazoline derivatives as tyrosine kinase inhi...

Call: PRELUDIUM 12 , Panel: NZ7

Principal investigator: Katarzyna Anna Malarz

Uniwersytet Śląski w Katowicach, Wydział Matematyki, Fizyki i Chemii

Use of novel small molecule inhibitors of PERK kinase dependent UPR pathway for the colorectal cancer treatment

Call: OPUS 12 , Panel: NZ5

Principal investigator: prof. Adam Janusz Dziki

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Analysis of the effectiveness of anticancer activity of tyrosine kinase inhibitors combined with nanoparticles in in vit...

Call: SONATA 11 , Panel: ST4

Principal investigator: dr Natalia Piergies

Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego Polskiej Akademii Nauk

Use of novel small molecule inhibitors of PERK kinase dependent UPR pathway for the primary open-angle glaucoma treatmen...

Call: OPUS 11 , Panel: NZ5

Principal investigator: prof. Ireneusz Jacek Majsterek

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

New opportunities for use of PERK kinase inhibitors in eIF2alfa factor-dependant signalling pathway in antitumor therapy

Call: PRELUDIUM 10 , Panel: NZ3

Principal investigator: dr Wioletta Julia Rozpędek-Kamińska

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Synthesis of new glutamate receptors antagonists and extensive investigation of their effect on tumor cells in the prese...

Call: OPUS 9 , Panel: ST5

Principal investigator: prof. Maria Wanda Bretner

Politechnika Warszawska, Wydział Chemiczny

New MOF compounds as degradable nanocontainers of tyrosine kinases inhibitors in novel anti-cancer therapy

Call: OPUS 9 , Panel: ST5

Principal investigator: prof. Artur Piotr Terzyk

Uniwersytet Mikołaja Kopernika w Toruniu, Wydział Chemii

Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

Call: PRELUDIUM 9 , Panel: NZ5

Principal investigator: Zofia Felicja Bielecka

Wojskowy Instytut Medyczny